Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Document Type
- Journal article (13)
Language
- English (13)
Keywords
- blood-brain barrier (2)
- blood-brain barrier (BBB) model (2)
- endothelial cells (2)
- in vitro (2)
- sepsis (2)
- stroke (2)
- 3D tissue model (1)
- Blut-Hirn-Schranke (1)
- C6 (1)
- CNS disease (1)
- Glucosetransportproteine (1)
- MK801 (1)
- NMDA-Antagonist (1)
- NMDA-Rezeptor (1)
- NMDAR (1)
- NOTCH (1)
- NSAIDs (1)
- OLFM4 (1)
- Salmonella Typhimurium (1)
- Schlaganfall (1)
- acute liver failure (1)
- alveolar epithelium in vitro model, claudin-1, claudin-3, claudin-4, claudin-5 (1)
- angiogenesis (1)
- astrocytes (1)
- bacterial migration (1)
- bacterial virulence (1)
- barrier (1)
- biofilm (1)
- biological barriers (1)
- biological scaffold (1)
- blood (1)
- blood‐brain barrier (BBB) (1)
- brain–liver chip (1)
- central nervous system (1)
- cerebEND (1)
- colloids (1)
- corticosteroids (1)
- creatinine (1)
- diazepam (1)
- drug permeability screening (1)
- drug-drug interactions (1)
- endotoxemia (1)
- exposure (1)
- expression (1)
- fetal lung (1)
- filamentous Salmonella Typhimurium (1)
- glioma (1)
- glucocorticoids (1)
- glut1 (1)
- histopathology (1)
- human exposure (1)
- human induced pluripotent stem cells (hiPSCs) (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human‐induced pluripotent stem cells (hiPSC) (1)
- infection (1)
- inflammation (1)
- intestinal enteroids (1)
- ischemia (1)
- kidneys (1)
- microbe carrier (1)
- microparticles (1)
- microphysiological systems (MPS) (1)
- microplastics (1)
- mouse models (1)
- multi-organ chip (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- nanoparticles (1)
- nanoplastics (1)
- neurotoxicity (1)
- neurovascular unit in vitro (1)
- olfactomedin 4 (1)
- oxygen/glucose deprivation (1)
- permeability (1)
- phosphodiesterase (1)
- preclinical drug discovery (1)
- pregnancy (1)
- preterm birth (1)
- protein expression (1)
- rat (1)
- rolipram (1)
- scanning electron microscopy (1)
- sglt1 (1)
- sheep (1)
- tight junctions (1)
- toxicity (1)
- transport inhibition assay (1)
- traumatic brain injury (1)
- urine (1)
Institute
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (8)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (5)
- Institut für Anatomie und Zellbiologie (2)
- Kinderklinik und Poliklinik (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Frauenklinik und Poliklinik (1)
- Institut für Molekulare Infektionsbiologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241778 (4)
- HEALTH-F2-2009-241778 (1)
During stroke the blood–brain barrier (BBB) is damaged which can result in vasogenic brain edema and inflammation. The reduced blood supply leads to decreased delivery of oxygen and glucose to affected areas of the brain. Oxygen and glucose deprivation (OGD) can cause upregulation of glucose uptake of brain endothelial cells. In this letter, we investigated the influence of MK801, a non-competitive inhibitor of the NMDA-receptor, on the regulation of the glucose uptake and of the main glucose transporters glut1 and sglt1 in murine BBB cell line cerebEND during OGD. mRNA expression of glut1 was upregulated 68.7- fold after 6 h OGD, which was significantly reduced by 10 μM MK801 to 28.9-fold. Sglt1 mRNA expression decreased during OGD which was further reduced by MK801. Glucose uptake was significantly increased up to 907% after 6 h OGD and was still higher (210%) after the 20 h reoxygenation phase compared to normoxia. Ten micromolar MK801 during OGD was able to reduce upregulated glucose uptake after OGD and reoxygenation significantly. Presence of several NMDAR subunits was proven on the mRNA level in cerebEND cells. Furthermore, it was shown that NMDAR subunit NR1 was upregulated during OGD and that this was inhibitable by MK801. In conclusion, the addition of MK801 during the OGD phase reduced significantly the glucose uptake after the subsequent reoxygenation phase in brain endothelial cells.